Russian Heart Failure Journal 2011year Association between methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism and left ventricular hypertrophy in patients on hemodialysis


To access this material please log in or register

Register Authorize
2011/

Association between methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism and left ventricular hypertrophy in patients on hemodialysis

Harlamova U. V., Iljicheva O. E.

Keywords: hemodialysis, myocardial hypertrophy, gene polymorphism

DOI: 10.18087/rhfj.2011.1.1460

Background. Identification of genetic factors involved in myocardial remodeling allows to understand the pathogenetic processes of hypertrophy in patients on hemodialysis. Objective. To define the role of MTHFR C677T gene polymorphism in the development of structural and functional changes of myocardium in patients on hemodialysis. Materials and methods. The study included 58 patients with end-stage chronic renal failure on hemodialysis. Molecular genetic detection of point MTHFR gene mutations, echocardiography wee performed. Results. MTHFR gene mutation was revealed in 22 patients (38 %) (CT genotype in 18 subjects and CT in 4 subjects). In 36 patients no mutations were detected (CC genotype). The rate of eccentric hypertrophy in the group with and without mutation did not differ significantly – 7 (32 %) and 16 (44 %), p=0.5; OR=0.58; 95 % CI (0.23; 1.56). There was a significant prevalence of concentric LVH in subjects with MTHFR gene mutation – 15 (68 %) and 14 (39 %), p=0.03. Genotype CT and TT increased the risk of concentric LVH in 3.37‑fold compared with CC homozygotes without mutation – OR=3,37; 95 % CI (1.3; 8.4). Significant association between MTHFR gene T-allele carriage and development of concentric LVH.
  1. Hwang SJ, Yang WC, Lin MY. Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan. Nephrology Dialysis Transplantation. 2010;25 (8):2616–2624.
  2. Manjunath G, Tighiouart H, Ibrahim H et al. Level of kidney function as a risk factors for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41 (1):47–55.
  3. Дядык А. И., Канелла Дж., Багрий А. Э. и др. Гипертрофия левого желудочка сердца у больных с хронической почечной недостаточно­стью. Укр. кардиол. журн. 2000;3:81–87.
  4. Locatelli F, Marcelli D, Conte F et al. Cardiovascular disease in chronic renal failure: the challenge continues. Registro Lombardo Dialisi e Trapianto. Nephrol Dial Transplant. 2000;15 (Suppl 5):69–80.
  5. Спиридонова М. Г., Степанов В. А., Пузырев В. П. О роли полиморфных вариантов гена 5,10‑метилентетрагидрофолатредук­тазы (MTHFR) в патогенезе сердечно-сосудистых заболеваний. Клин мед. 2001;2:10–16.
  6. Giusti B, Porciani MC, Brunelli T et al. Phenotypic variability of cardiovascular manifestations in Marfan syndrome: possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism. Eur Heart J. 2003;24 (22):2038–2045.
  7. Liu X, Luo F, Li J et al. Homocysteine induces connective tissue grows factor expression in vascular smooth muscle cells. J Thromb Haemost. 2008;6 (1):184–192.
  8. Blacher J, Benetos A, Kirzin J et al. Relation of plasma homocysteine to cardiovascular mortality in a French population. Am J Cardiol. 2002;90 (6):591–595
  9. Mallamaci F, Zoccali C, Tripepi G et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int. 2002;61 (2):609–614.
  10. Genser D. Homocysteine, vitamins, and restenosis after percutaneous coronary intervention. Cardiovasc Rev Rep. 2003;24 (5):253–258.
  11. Brattstrom L, Wicken D. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr. 2000;72 (2):315–323.
  12. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr. 2000;72 (2):324–332.
  13. Reyes-Engel A, Morel M, Aranda F et al. Plasma homocysteine levels, C667T polymorphism of methylenetetrahydrofalate reductasa gene, plasma renin activity and cardiovascular risk. Am J Hypertens. 2002;14 (4):154.
  14. Motulsky A. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet. 1996;58 (1):17–20.
  15. Aucella F, Margaglione M, Grandone E et al. The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multicentre prospective study. Nephrol Dial Transplant. 2005;20 (2):382–386.
  16. Gardemann A, Weidemann H, Philipp M et al. The TT genotype of the methylenetetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease. Eur Heart J. 1999;20 (8):584–592.
  17. Кузнецова Т. Ю., Дуданов И. П., Гаврилов Д. В. и др. Хроническая сердечная недостаточность у пациентов с артериальной гипертензией и полиморфизмы Glu298Asp гена эндотелиальной NO-синтазы и С242Тp22phox гена NADPH-оксидазы. Журнал Сердечная недостаточность. 2007;8 (6):274–275.
  18. Гончарова Л. Н., Бирлюкова Д. В., Хасанова З. Б. и др Роль генов ренин-ангиотензиновой системы в формировании хронической сердечной недостаточности у лиц с семейной артериальной гипертензией коренных жителей Республики Мордовия. Журнал Сердечная недостаточность. 2008;9 (6): 274–275.
  19. Khawaja MR Taj F, Ahmad U et al. Association of endothelial nitric oxide synthase gene G894T polymorphism with essential hypertension in an adult Pakistani Pathan population. Int J Cardiol. 2007;116 (1):113–115.
Harlamova U. V., Iljicheva O. E. Association between methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism and left ventricular hypertrophy in patients on hemodialysis. 2011;12(1):23-26.

To access this material please log in or register

Register Authorize
Ru En